Literature DB >> 21566656

The heterogeneity of pediatric MLL-rearranged acute myeloid leukemia.

B V Balgobind1, C M Zwaan, R Pieters, M M Van den Heuvel-Eibrink.   

Abstract

Translocations involving the mixed-lineage leukemia (MLL) gene, localized at 11q23, comprise 15 to 20% of all pediatric acute myeloid leukemia (AML) cases. This review summarizes current knowledge about the etiology, biology, clinical characteristics and differences in outcome in MLL-rearranged pediatric AML. Furthermore, we discuss the role of cooperating events in MLL-rearranged pediatric AML, and future therapeutic strategies to improve outcome. We conclude that MLL-rearranged pediatric AML is a heterogeneous disease, and prognosis depends on various factors, for example, translocation partner, age, WBC and additional cytogenetic aberrations. The relationship of outcome with specific translocation partners requires that they be searched for in the diagnostic work-up of AML. To achieve further improvements in outcome, unraveling the biology of MLL-rearranged pediatric AML is warranted.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21566656     DOI: 10.1038/leu.2011.90

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  46 in total

1.  Mechanisms of mixed-lineage leukemia.

Authors:  Andrew G Muntean
Journal:  Int J Hematol Oncol       Date:  2013-06-01

2.  Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.

Authors:  Anilkumar Gopalakrishnapillai; E Anders Kolb; Suzanne M McCahan; Sonali P Barwe
Journal:  Leuk Res       Date:  2017-05-05       Impact factor: 3.156

3.  Identification of functional cooperative mutations of SETD2 in human acute leukemia.

Authors:  Xiaofan Zhu; Fuhong He; Huimin Zeng; Shaoping Ling; Aili Chen; Yaqin Wang; Xiaomei Yan; Wei Wei; Yakun Pang; Hui Cheng; Chunlan Hua; Yue Zhang; Xuejing Yang; Xin Lu; Lihua Cao; Lingtong Hao; Lili Dong; Wei Zou; Jun Wu; Xia Li; Si Zheng; Jin Yan; Jing Zhou; Lixia Zhang; Shuangli Mi; Xiaojuan Wang; Li Zhang; Yao Zou; Yumei Chen; Zhe Geng; Jianmin Wang; Jianfeng Zhou; Xin Liu; Jianxiang Wang; Weiping Yuan; Gang Huang; Tao Cheng; Qian-Fei Wang
Journal:  Nat Genet       Date:  2014-02-09       Impact factor: 38.330

4.  Shp2 regulates leukemic stem cell frequency in MLL-rearranged acute myeloid leukemia.

Authors:  Jie Wu
Journal:  Stem Cell Investig       Date:  2015-04-16

5.  Harnessing Gene Expression Profiles for the Identification of Ex Vivo Drug Response Genes in Pediatric Acute Myeloid Leukemia.

Authors:  David G J Cucchi; Costa Bachas; Marry M van den Heuvel-Eibrink; Susan T C J M Arentsen-Peters; Zinia J Kwidama; Gerrit J Schuurhuis; Yehuda G Assaraf; Valérie de Haas; Gertjan J L Kaspers; Jacqueline Cloos
Journal:  Cancers (Basel)       Date:  2020-05-15       Impact factor: 6.639

6.  PU.1 is essential for MLL leukemia partially via crosstalk with the MEIS/HOX pathway.

Authors:  J Zhou; J Wu; B Li; D Liu; J Yu; X Yan; S Zheng; J Wang; L Zhang; L Zhang; F He; Q Li; A Chen; Y Zhang; X Zhao; Y Guan; X Zhao; J Yan; J Ni; M A Nobrega; B Löwenberg; R Delwel; P J M Valk; A Kumar; L Xie; D G Tenen; G Huang; Q-F Wang
Journal:  Leukemia       Date:  2013-12-26       Impact factor: 11.528

Review 7.  Revisiting the biology of infant t(4;11)/MLL-AF4+ B-cell acute lymphoblastic leukemia.

Authors:  Alejandra Sanjuan-Pla; Clara Bueno; Cristina Prieto; Pamela Acha; Ronald W Stam; Rolf Marschalek; Pablo Menéndez
Journal:  Blood       Date:  2015-10-13       Impact factor: 22.113

8.  The efficiency of murine MLL-ENL-driven leukemia initiation changes with age and peaks during neonatal development.

Authors:  Theresa Okeyo-Owuor; Yanan Li; Riddhi M Patel; Wei Yang; Emily B Casey; Andrew S Cluster; Shaina N Porter; David Bryder; Jeffrey A Magee
Journal:  Blood Adv       Date:  2019-08-13

Review 9.  Childhood acute myeloid leukaemia.

Authors:  Jeffrey E Rubnitz; Hiroto Inaba
Journal:  Br J Haematol       Date:  2012-09-12       Impact factor: 6.998

10.  Upregulation of Flt3 is a passive event in Hoxa9/Meis1-induced acute myeloid leukemia in mice.

Authors:  A Staffas; L S Arabanian; S Y Wei; A Jansson; S Ståhlman; P Johansson; L Fogelstrand; J Cammenga; F Kuchenbauer; L Palmqvist
Journal:  Oncogene       Date:  2016-09-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.